New strategies in lung cancer: translating immunotherapy into clinical practice
about
Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intentThe efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment.CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice.Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung CancerNon-small-cell lung cancers: a heterogeneous set of diseases.Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review.Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Cell death-based treatment of lung adenocarcinoma.The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
P2860
Q24194081-7927459F-A9B1-4FB5-A62A-74DBB6348137Q33434828-5A953517-D210-41BE-BA6E-F3051CC1521CQ34306441-994F0D99-18FF-4398-9B8E-480DF77A1DDAQ34976095-F3DD6836-B866-47AE-8F8E-95E97EF493DBQ35612583-7535E5CD-5C64-4930-B6AD-F27A87F90802Q36909904-948972ED-E29F-4024-A2D6-4E9E3A59E99FQ38233321-AE301454-629C-4831-9422-E83783E63E86Q38366141-B663A36B-3559-4964-888E-CD682021A2DFQ38699858-8A92FC8F-3FC7-4F3E-93F0-BEE80A763E1FQ38837187-0AB88DD7-AB9B-47AB-9815-CD343371E525Q41143313-8A5DAE5C-7135-454F-90B2-FB3C87CD3613Q47299048-735926E9-B361-4A5C-BA48-43EAE3CF84D2Q47711273-D401A25A-AA64-4D45-8238-C8D28B03ECB1Q49242745-11242693-225D-404A-B2F4-9B63049D3768
P2860
New strategies in lung cancer: translating immunotherapy into clinical practice
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New strategies in lung cancer: translating immunotherapy into clinical practice
@ast
New strategies in lung cancer: translating immunotherapy into clinical practice
@en
New strategies in lung cancer: translating immunotherapy into clinical practice
@nl
type
label
New strategies in lung cancer: translating immunotherapy into clinical practice
@ast
New strategies in lung cancer: translating immunotherapy into clinical practice
@en
New strategies in lung cancer: translating immunotherapy into clinical practice
@nl
prefLabel
New strategies in lung cancer: translating immunotherapy into clinical practice
@ast
New strategies in lung cancer: translating immunotherapy into clinical practice
@en
New strategies in lung cancer: translating immunotherapy into clinical practice
@nl
P2093
P3181
P1476
New strategies in lung cancer: translating immunotherapy into clinical practice
@en
P2093
J. R. Brahmer
P. M. Forde
R. J. Kelly
P304
P3181
P356
10.1158/1078-0432.CCR-13-0731
P407
P577
2014-03-01T00:00:00Z